HLB innoVationHLB이노베이션

HLB Innovation reports deep operating losses on a 27% revenue rise in 2025, while its shares have run up sharply over three months.

HLB Innovation makes semiconductor lead frames and chip-test contact pins and is also developing CAR-T cell therapies through its U.S. subsidiary Verismo Therapeutics. Trailing revenue is about ₩35.8B, but operating losses are about ₩37.8B and the company has negative free cash flow. The shares closed at ₩14,860 on 2026-10-26, up 80.8% over three months but down 1.8% over one month.

What stands out

• Trailing twelve-month operating margin is -105.8% and net margin is -91.2%, with 2025 operating margin at -116.4%, so losses are large relative to sales.
• Revenue grew 27.2% in 2025 to about ₩32.3B, but operating loss widened to about ₩37.6B from ₩11.9B in 2024.
• Trailing cash of about ₩55.4B sits against borrowings of about ₩38.1B, and trailing free cash flow is about -₩29.3B.
• Recent filings include a conversion price adjustment, a rights offering decision, short-term borrowing changes and several 5%+ holding reports, which point to ongoing financing activity.
• Valuation metrics are mixed: price-to-book is 2.1, price-to-sales is 14.4, and earnings-based ratios are not available because earnings are negative. The data does not include analyst ratings or price targets.
• Foreign ownership is recorded at 0%, and 20-day flows show institutional net selling of about ₩9.1B against retail net buying of about ₩7.7B.

What to watch

• The rights offering and conversion price adjustment, which could affect share count and dilution; the data does not give the terms.
• Next periodic filings and whether operating losses narrow from the current trailing level.
• Preclinical CAR-T news from Verismo, which the data shows as early-stage with no clinical revenue indicated.